Marimed (MRMD) Stock News

MariMed Inc. (OTCQX: MRMD) reported its Q2 2025 financial results, showing mixed performance. Revenue reached $39.6 million, slightly down from $40.4 million in Q2 2024. The company posted a GAAP net loss of $1.3 million but achieved non-GAAP Adjusted EBITDA of $4.9 million, up from $4.4 million year-over-year.

Key operational highlights include launching Nature's Heritage™ products in Illinois, introducing new Betty's Eddies™ caramel chews, and expanding to Maine through a licensing partnership. The company also announced a significant Managed Services Agreement in Pennsylvania with TILT Holdings, positioning for potential adult-use market expansion.

Despite challenges, MariMed maintained strong gross margins of 40% GAAP and 42% non-GAAP, while implementing its 'Expand the Brand' strategy across core markets.

MariMed (OTCQX: MRMD) has entered into a strategic Management Services Agreement (MSA) with TILT Holdings' subsidiary Standard Farms to expand into Pennsylvania's medical marijuana market. Starting September 1, 2025, MariMed will manage TILT's cultivation and processing facility in White Haven, Pennsylvania.

Under the 4-year agreement, MariMed will receive a 12.5% management fee of Standard Farms' gross revenue. The company will oversee daily operations, including budgeting, financial planning, compliance, and quality management. Additionally, Standard Farms will produce and distribute MariMed's branded products in Pennsylvania through a licensing arrangement.

MariMed (OTCQX: MRMD) has announced a new licensing agreement with The Stoned Moose to expand distribution of its Betty's Eddies™ full-spectrum fruit chews in Maine's $455 million cannabis market. The partnership will extend the brand's reach to include both adult-use and medical cannabis consumers, with medical sales representing over half of Maine's cannabis revenues in 2024.

Previously available only to adult-use consumers since 2022, Betty's Eddies will now be accessible to medical cannabis patients through The Stoned Moose's dual-license capabilities. The brand currently holds market leadership in edibles across Massachusetts, Maryland, and Delaware, targeting Maine's local consumer base and its 15 million annual tourists.

MariMed (OTCQX: MRMD) has announced a new licensing agreement with The Stoned Moose to expand distribution of its Betty's Eddies™ full-spectrum fruit chews in Maine's $455 million cannabis market. The partnership will extend the brand's reach to include both adult-use and medical cannabis consumers.

Previously available only to adult-use consumers since 2022, Betty's Eddies will now be accessible to medical cannabis patients, a significant market segment that represented over half of Maine's cannabis revenues in 2024. The brand currently leads market share for edibles in Massachusetts, Maryland, and Delaware.

MariMed Inc. (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, has scheduled its second quarter 2025 earnings release for August 6, 2025, after market close.

The company will host a conference call to discuss the financial results on August 7, 2025, at 8:00 a.m. EDT. Investors can access the webcast through MariMed's Investor Relations website, where a playback will also be available following the call.

MariMed (MRMD) has announced its readiness to participate in Delaware's expansion into adult-use cannabis sales, which will commence on August 1st, 2025. Through its Delaware business unit, First State Compassion (FSC), which has been the state's first licensed operator for 10 years, MariMed has already implemented improvements at its dispensaries in Wilmington and Lewes to handle increased customer traffic.

The company has begun scaling production at its cultivation and processing facilities in Wilmington and Milford to meet anticipated demand from both residents and the nearly 30 million annual tourists. MariMed's product portfolio in Delaware includes Betty's Eddies chews, currently the state's top-selling edible, along with FSC and Nature's Heritage flower brands, both ranking in the top five.

[ "First-mover advantage as Delaware's first licensed cannabis operator", "Strategic positioning with two dispensary locations in Wilmington and Lewes", "Market leadership with top-selling products including #1 edible brand", "Access to potential market of 30 million annual tourists", "Facilities already upgraded to handle increased customer traffic" ]

MariMed (MRMD) has launched MycroDose by Nature's Heritage, a new line of vegan wellness products combining cannabis with functional mushrooms in pill form. The product line features four distinct formulations available in Massachusetts dispensaries: Chill: For relaxation and stress relief, containing THC, CBD, Cordyceps, Lion's Mane, and Ashwagandha. G'Night: For improved sleep, featuring THC, CBN, CBD, Reishi, Lion's Mane, Chamomile, and Magnesium. Remedy: For inflammation reduction, including THC, CBD, CBC, Oyster mushroom, Ginger, Turmeric, and Piperine. Spark: For energy and focus, combining THCV, THC, Shiitake, Lion's Mane, and Ginseng. The products are currently available at MariMed's Panacea Wellness stores and select Massachusetts dispensaries.

MariMed Inc. (MRMD) reported its Q1 2025 financial results with revenue of $38.0 million, showing minimal growth from $37.9 million in Q1 2024. The company experienced declining profitability with GAAP net loss widening to $5.4 million from $1.3 million year-over-year. Gross margins decreased to 40% from 43%, while Adjusted EBITDA dropped to $2.6 million from $4.7 million. Despite challenges, wholesale sales now represent 44% of revenue mix, with the company's Betty's Eddies™ cannabis chews maintaining market leadership in multiple states. Notable developments include completing the First State Compassion Center acquisition in Delaware, launching Nature's Heritage™ products in Illinois, and introducing new Betty's Eddies™ caramel chews. The company appointed Ryan Crandall as Chief Commercial Officer to lead commercial strategy.

MariMed (CSE: MRMD, OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, has scheduled its first quarter 2025 earnings release for May 7, 2025 after market close.

The company will host a conference call to discuss the financial results on May 8, 2025 at 8:00 a.m. EDT. Investors can access the webcast through MariMed's Investor Relations website, where a playback will also be available after the call.